As of December 31, 2025, Cogent had cash, cash equivalents and marketable securities of $900.8 million. Fourth quarter cash usage was driven largely by non-recurring items, including the repayment of $54.8 million of long-term debt and approximately $38.5 million of one-time, performance-based equity compensation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
- Cogent Biosciences announcse U.S. BTD for bezuclastinib
- Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
- Cogent to initiate New Drug Application submission for bezuclastinib
- Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target